Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Jul:353:33-40.
doi: 10.1016/j.atherosclerosis.2022.04.019. Epub 2022 Apr 25.

Suboptimal HIV suppression is associated with progression of coronary artery stenosis: The Multicenter AIDS Cohort Study (MACS) longitudinal coronary CT angiography study

Wendy S Post  1 , Sabina A Haberlen  2 , Mallory D Witt  3 , Long Zhang  2 , Lisa P Jacobson  2 , Todd T Brown  4 , Joseph B Margolick  5 , Lawrence Kingsley  6 , Frank J Palella Jr  7 , Matthew Budoff  3
Affiliations
Multicenter Study

Suboptimal HIV suppression is associated with progression of coronary artery stenosis: The Multicenter AIDS Cohort Study (MACS) longitudinal coronary CT angiography study

Wendy S Post et al. Atherosclerosis. 2022 Jul.

Abstract

Background and aims: People living with HIV (HIV+) are surviving longer due to effective antiretroviral therapy. Cardiovascular disease is a leading cause of non-AIDS related clinical events. We determined HIV-related factors associated with coronary artery stenosis progression.

Methods: We performed serial coronary CT angiography among HIV+ and HIV-uninfected (HIV-) men in the Multicenter AIDS Cohort Study. The median inter-scan interval was 4.5 years. Stenosis was graded as 0, 1-29, 30-49, 50-69 or ≥70%. Progression was defined as an increase ≥2 categories. Suppressed HIV infection was consistent viral loads <50 copies/mL allowing 1 "blip" <500 copies/mL, otherwise considered viremic. Multivariable Poisson regression analysis assessed adjusted associations between HIV serostatus and viremia with coronary stenosis progression.

Results: The sample included 310 HIV+ (31% viremic) and 234 HIV- men. The median age was 53 years, 30% Black and 23% current smokers. Viremic men were 2.3 times more likely to develop coronary stenosis progression than HIV- men (adjusted RR 2.30; 95% CI, 1.32-4.00, p = 0.003), with no difference in progression between HIV+ suppressed and HIV- men (RR 1.10; 95% CI, 0.70-1.74, p = 0.67). There was a progressive increase in adjusted relative risk with greater viremia (p = 0.03). Men with >1 viral load >500 copies/ml demonstrated greatest stenosis progression (RR 3.01; 95% CI, 1.53-4.92, p = 0.001 compared with HIV- men). Suppressed HIV+ men with suboptimal antiretroviral adherence had greater stenosis progression (RR 1.91; 95% CI 1.12-3.24, p = 0.02) than HIV + suppressed men with optimal adherence.

Conclusions: Coronary artery stenosis progression was associated with suboptimal HIV RNA suppression and antiretroviral therapy adherence. Effective ongoing HIV virologic suppression and antiretroviral therapy adherence may mitigate risk for coronary disease events among people living with HIV.

Keywords: Atherosclerosis; Coronary CT angiography; Coronary artery disease; Epidemiology; HIV.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest:

TTB has served as a consultant to Gilead Sciences, ViiV Healthcare, Janssen, Merck, and Theratechnologies. FJP is a consultant and/or on the Speakers’ Bureau for Gilead, Janssen, ViiV and Merck. The remaining authors do not have any relationship with industry.

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1.
Figure 1.. Participant flow diagram.
The participant flow diagram is displayed. eGFR=estimate glomerular filtration rate; aparticipant excluded due to low eGFR documented between baseline CTA and enrollment screening for the follow-up CTA scan; bparticipant was enrolled for follow-up scan, but did not receive contrast CTA due to low eGFR at the study visit.
Figure 2.
Figure 2.. Adjusted relative risk of stenosis progression by HIV viremic group.
The adjusted relative risks for coronary artery stenosis progression are presented. Relative risks are adjusted for age, race, education, study site, cohort enrollment date, interval scan time, CVD risk factors and cocaine use. Upper panel (A) sample sizes by outcome: 1) segment-level stenosis, HIV+ Viremic=1,299 segments/98 ids, HIV+ suppressed=2,793 segments/212 ids, and HIV−=3,104 segments/234 ids, 2) incident stenosis, HIV+ Viremic=85, HIV+ Suppressed=180, and HIV−=203, and 3) vessel-involvement progression, HIV+ Viremic=97, HIV+ Suppressed=211, and HIV−=230. HIV=human immunodeficiency virus, RR=relative risk, VL=viral load.
See this image and copyright information in PMC

Comment in

References

    1. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. American journal of epidemiology. 2013;177(2):116–25. - PMC - PubMed
    1. Lerner AM, Eisinger RW, Fauci AS. Comorbidities in Persons With HIV: The Lingering Challenge. JAMA. 2019. - PubMed
    1. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation. 2019;140(2):e98–e124. - PMC - PubMed
    1. Post WS, Budoff M, Kingsley L, Palella FJ Jr., Witt MD, Li X, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med. 2014;160(7):458–67. - PMC - PubMed
    1. Strategies for Management of Antiretroviral Therapy Study G, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. The New England journal of medicine. 2006;355(22):2283–96. - PubMed

Publication types